公开(公告)号：WO2023067577A1

公开(公告)日：2023-04-27

申请号：PCT/IB2022/060159

申请日：2022-10-21

申请人： UNIVERSITY HEALTH NETWORK

发明人： HIRANO, Naoto ,  MURATA, Kenji ,  LY, Dalam ,  SAIJO, Hiroshi ,  MATSUNAGA, Yukiko

IPC分类号： C07K14/74 ,  A61K31/7088 ,  A61K38/17 ,  A61K38/46 ,  A61P35/00 ,  A61P37/02 ,  C12N15/10 ,  C12N15/12

摘要： The present disclosure is directed to methods of modifying an HLA-binding pocket in an HLA molecule in a subject. Some aspects are directed to HLA molecules comprising a modified HLA-binding pocket, where the HLA molecule has increased affinity for a peptide, e.g., an antigen. Other aspects are directed to compositions comprising the same and methods of using the same.

公开(公告)号：WO2022269393A1

公开(公告)日：2022-12-29

申请号：PCT/IB2022/055149

申请日：2022-06-01

申请人： CRISPR THERAPEUTICS AG

发明人： SLUCH, Valentin ,  SWAIN, Danielle ,  REZANIA, Alireza

IPC分类号： C12N5/0783 ,  A61K35/17 ,  A61P35/00 ,  C07K14/74 ,  C07K14/725 ,  C07K14/5443 ,  C07K14/70539 ,  C07K14/7155 ,  C07K14/8121 ,  C07K2319/00 ,  C07K2319/02 ,  C12N15/625 ,  C12N15/85 ,  C12N15/907 ,  C12N2310/20 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/2303 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/26 ,  C12N2501/415 ,  C12N2501/515 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2800/107 ,  C12N5/0646 ,  C12N5/067 ,  C12N5/0696 ,  C12N9/22

摘要： Provided herein are cells engineered to have improved protection against natural killer cell killing. The cells are engineered to comprise an insertion of a polynucleotide encoding SERPINB9. Also provided herein are methods of making the engineered cells and therapeutic uses of the engineered cells. The engineered cells can also comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor. The engineered cells can be stem cells and the engineered stem cells can be differentiated into various lineages having protection against NK cell killing.

公开(公告)号：WO2022226069A1

公开(公告)日：2022-10-27

申请号：PCT/US2022/025547

申请日：2022-04-20

申请人： CUE BIOPHARMA, INC.

发明人： SEIDEL III, Ronald D. ,  CHAPARRO, Rodolfo J. ,  LOW, Chee Meng

IPC分类号： C07K14/47 ,  C07K14/74 ,  A61P3/10 ,  A61K38/00

摘要： The present disclosure provides T-cell modulatory polypeptides (TMPs) comprising a type 1 diabetes (T1D)-associated peptide epitope, MHC class II polypeptides, one or more immunomodulatory polypeptides, a TGF-β polypeptide, and a masking polypeptide. A TMP of the present disclosure is useful for modulating activity of a T cell. Thus, the present disclosure provides compositions and methods for modulating the activity of T cells, as well as compositions and methods for treating persons who have T1D.

公开(公告)号：WO2022192701A1

公开(公告)日：2022-09-15

申请号：PCT/US2022/019995

申请日：2022-03-11

申请人： T-CURE BIOSCIENCE, INC. ,  VON EUW, Erika ,  DAVIS, Nicholas ,  PARRY, Gordon ,  ZENG, Gang

发明人： VON EUW, Erika ,  DAVIS, Nicholas ,  PARRY, Gordon ,  ZENG, Gang

IPC分类号： A61K35/17 ,  C07K14/725 ,  C07K14/74 ,  C12Q1/6881

摘要： The present invention provides methods for increasing the sensitivity of tumor cells to a TCR-engineered T cells (TCR-T) therapy comprising genetically modifying the tumor cells to express an haplotype, for example an HLA haplotype, different from the haplotype endogenous to the tumor cells.

公开(公告)号：WO2022133155A1

公开(公告)日：2022-06-23

申请号：PCT/US2021/063931

申请日：2021-12-16

申请人： XENOTHERAPEUTICS, INC. ,  XENOTHERAPEUTICS CORPORATION

发明人： HOLZER, Paul W. ,  MONROY, Rodney L. ,  CHANG, Elizabeth J. ,  ROGERS, Kaitlyn

IPC分类号： A01K67/027 ,  C12N5/078 ,  C07K14/74

摘要： A method of modifying copy (1) and copy (2) of the β2-microglobulin (β2M) gene of a porcine donor animal, genetically modified porcine donor animal wherein copy (1) and copy (2) of the β2M gene of the porcine donor animal genome are modified, and a method of producing a donor porcine donor animal tissue or organ for xenotransplantation, wherein copy (1) and copy (2) of the β2M gene of the cells of said donor porcine donor animal are modified. A method of humanizing a genetically engineered donor animal by modification of the donor animal's expressed native β2-microglobulin protein through genetic alterations of the endogenous β2M genes, and as a result, the newly expressed β2M protein of the donor animal would contain some or all of the amino acids of the orthologous human β2-microglobulin (hβ2M) protein, in identity and orientation. This results in immune-compatible xenotransplants between donor animals and human recipients.

公开(公告)号：WO2022008418A1

公开(公告)日：2022-01-13

申请号：PCT/EP2021/068471

申请日：2021-07-05

申请人： IMMUNOCORE LIMITED

发明人： LEONARD, Sarah ,  PATERSON, Rachel ,  DE SOUZA, Victoria Arena ,  DEMBEK, Marcin

IPC分类号： C07K16/12 ,  C07K14/74 ,  C07K16/28 ,  C07K14/725

摘要： The present invention relates to specific binding molecules which bind to the HLA-E restricted peptide RLPAKAPLL (SEQ ID NO: 1) derived from Mycobacterium tuberculosis enoyl-ACP reductase. Said specific binding molecules may comprise CDR sequences embedded within a framework sequence. The CDRs and framework sequences may correspond to a T cell receptor (TCR) variable domain and may further comprise non-natural mutations relative to a native TCR variable domain. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of infectious disease.

公开(公告)号：WO2021207826A1

公开(公告)日：2021-10-21

申请号：PCT/CA2021/050471

申请日：2021-04-09

申请人： UNIVERSITÉ DE MONTRÉAL

发明人： PERREAULT, Claude ,  THIBAULT, Pierre ,  HARDY, Marie-Pierre

IPC分类号： C07K14/47 ,  A61K39/00 ,  A61K39/395 ,  A61K9/127 ,  A61P35/02 ,  A61P37/04 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C07K16/28 ,  C07K16/46 ,  C07K17/02 ,  C07K7/06 ,  C12N5/078 ,  C12N5/10

摘要： Acute lymphoblastic leukemia (ALL) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) specifically expressed by ALL cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, antibodies and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, antibodies, cells and vaccines for the treatment of leukemia such as ALL is also described.

公开(公告)号：WO2021172596A1

公开(公告)日：2021-09-02

申请号：PCT/JP2021/007779

申请日：2021-03-01

申请人： 国立大学法人金沢大学 ,  日産化学株式会社

发明人： 華山　力成 ,  山野　友義 ,  的場　一隆

IPC分类号： C12N15/62 ,  A61K35/15 ,  A61K38/19 ,  A61P35/00 ,  A61P37/06 ,  A61P37/08 ,  C07K14/52 ,  C07K14/74 ,  C07K19/00 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/12 ,  C12N15/19 ,  C12N15/63

摘要： 抗原特異的なＴ細胞を満足に活性化等することが可能な細胞外小胞を作製できるポリヌクレオチドを提供すること。　（ａ）抗原提示ＭＨＣ分子を含み、該抗原提示ＭＨＣ分子を細胞外小胞の膜外に提示可能な融合タンパク質（Ａ）をコードする配列；　（ｂ）すくなくとも１種のＴ細胞刺激性サイトカイン又はそのサブユニットを含む、該Ｔ細胞刺激性サイトカインを細胞外小胞の膜外に提示可能な融合タンパク質（Ｂ）をコードする配列；　（ｃ）Ｔ細胞共刺激分子を含む、該Ｔ細胞共刺激分子を細胞外小胞の膜外に提示可能な融合タンパク質（Ｃ）をコードする配列；　（ｄ）抗原提示ＭＨＣ分子と、すくなくとも１種のＴ細胞刺激性サイトカインまたはそのサブユニットを含み、該抗原と該Ｔ細胞刺激性サイトカインを細胞外小胞の膜外に提示可能な融合タンパク質（Ｄ）をコードする配列；及び　（ｅ）抗原提示ＭＨＣ分子と、すくなくとも１種のＴ細胞刺激性サイトカインまたはそのサブユニット、及びＴ細胞共刺激分子を含み、該抗原と該Ｔ細胞刺激性サイトカインと該Ｔ細胞共刺激分子を細胞外小胞の膜外に提示可能な融合タンパク質（Ｅ）をコードする配列； からなる群から選択されるすくなくとも１つの配列を含むポリヌクレオチドを提供する。

公开(公告)号：WO2021141456A1

公开(公告)日：2021-07-15

申请号：PCT/KR2021/000281

申请日：2021-01-08

申请人： 주식회사 엘지화학

发明人： 신준호 ,  권준철 ,  김승해

IPC分类号： C12N15/62 ,  C07K14/74 ,  C07K14/47 ,  C12N5/0784 ,  A61K31/7088 ,  A61K39/00 ,  A61P35/00

摘要： MHC (major histocompatibility complex) 및 종양 항원의 복합체가 세포 표면에 과발현된 항원제시세포 (antigen presenting cell)를 포함하는 암 예방 또는 치료용 백신 조성물 및 이를 이용한 암 치료에 관한 것이다.

公开(公告)号：WO2021119424A1

公开(公告)日：2021-06-17

申请号：PCT/US2020/064507

申请日：2020-12-11

申请人： EPIVAX, INC.

发明人： MOISE, Lenny ,  GUTIERREZ, Andres ,  MARTIN, William ,  DE GROOT, Anne

IPC分类号： A61K39/12 ,  C07K7/06 ,  C07K14/01 ,  C07K14/725 ,  C07K14/74

摘要： The present disclosure generally relates to a T-cell epitope compounds and compositions effective against African Swine Fever Virus ("ASFV") and related diseases. Such T-cell epitope compounds and compositions include immunogenic T-cell epitope polypeptides (including concatemeric polypeptides and chimeric or fusion polypeptides), as well as nucleic acids, plasmids, vectors, and cells which express the polypeptides, pharmaceutical compositions, and vaccines, and the uses thereof. The present disclosure is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against ASFV infection and related diseases.